Tetranitrin

Tetranitrin

SCHEMBL613474

O=[N+]([O-])OCC(O[N+](=O)[O-])C(CO[N+](=O)[O-])O[N+](=O)[O-]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
GSR P00390 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Erythrityl Tetranitrate SCHEMBL1816345 1.00 ALDH1A1 (0.40) ALDH1A1GSR
Tetranitrin SCHEMBL16541075 1.00 ALDH1A1 (0.40) ALDH1A1GSR
Erythrityl Tetranitrate SCHEMBL119876 1.00 ALDH1A1 (0.40) ALDH1A1GSR
SCHEMBL21493267 0.89 GSR (0.38) ALDH1A1GSR
SCHEMBL2957599 0.89 GSR (0.38) ALDH1A1GSR
Mannitol Hexanitrate SCHEMBL220255 0.88 ALDH1A1 (0.36) ALDH1A1
Mannitol Hexanitrate SCHEMBL57515 0.88 ALDH1A1 (0.36) ALDH1A1
SCHEMBL16541089 0.88 ALDH1A1 (0.36) ALDH1A1
SCHEMBL23370731 0.86 ALDH1A1 (0.34) ALDH1A1
Erythrityl Tetranitrate SCHEMBL1269391 0.85 GSR (0.36) ALDH1A1GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12212923-B2 First-order differential microphone array with steerable beamformer NORTHWESTERN POLYTECHNICAL UNIVERSITY (CN) 2025-01-28 US claimed
CN-119112554-A Xinkang intelligent service cabin 北京学能通科技集团有限公司 2024-12-13 CN claimed
US-20260149923-A1 AUDIO SYSTEM FOR VEHICLE TYMPHANY HK LIMITED (HK) 2026-05-28 US disclosed
EP-4289398-B1 IMPROVEMENTS FOR PROSTHETIC VALVES AND RELATED INVENTIONS TENDYNE HOLDINGS INC (US) 2026-05-27 EP disclosed
WO-2026106168-A1 COOKING APPARATUS AND CONTROL METHOD THEREFOR 삼성전자주식회사 2026-05-21 WO disclosed
WO-2026106170-A1 ELECTRONIC DEVICE AND CONTROL METHOD THEREOF 삼성전자주식회사 2026-05-21 WO disclosed
US-20260122416-A1 MICROPHONE ASSEMBLY AND SYSTEM ADAPTED TO FORM CONTINUOUSLY VARIABLE POLAR PATTERNS LOGITECH EUROPE SA (CH) 2026-04-30 US disclosed
US-20260122386-A1 MICROPHONE ASSEMBLY ADAPTED TO FORM CONTINUOUSLY VARIABLE POLAR PATTERNS LOGITECH EUROPE SA (CH) 2026-04-30 US disclosed
EP-4018680-B1 TWO-DIMENSIONAL MICROPHONE ARRAY WITH IMPROVED DIRECTIVITY SHURE ACQUISITION HOLDINGS INC (US) 2026-04-29 EP disclosed
EP-4710562-A1 MULTI-DIMENSIONAL ARRAY MICROPHONE Shure Acquisition Holdings, Inc. (US) 2026-03-18 EP disclosed
US-12532130-B2 Hearing device comprising a directional system configured to adaptively optimize sound from multiple target positions OTICON A/S (DK) 2026-01-20 US disclosed
WO-2006116499-A1 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA MICROBIA, INC. (US) 2006-11-02 WO disclosed
WO-2006086562-A2 PHENYLAZETIDINONE DERIVATIVES MICROBIA, INC. (US) 2006-08-17 WO disclosed
WO-2006086653-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS MICROBIA, INC. (US) 2006-08-17 WO disclosed
WO-2005112872-A1 PEROXIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF SEXUAL DYSFUNCTION IN HUMANS MIDWEST RESEARCH LABORATORIES, LLC (US) 2005-12-01 WO disclosed
EP-1541175-A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions Schering Corporation (US) 2005-06-15 EP disclosed
CN-1582168-A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions SCHERING CORP (US) 2005-02-16 CN disclosed
EP-1385548-A2 COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS Schering Corporation (US) 2004-02-04 EP disclosed
US-20030069221-A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions SCHERING CORPORATION 2003-04-10 US disclosed
WO-2002058731-A2 COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS SCHERING CORPORATION (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12532130-B2 Hearing device comprising a directional system configured to adaptively optimize sound from multiple target positions HINT1, WHR1, HIRA ALDH1A1 4211/4885GSR 2606/4885
US-20260122386-A1 MICROPHONE ASSEMBLY ADAPTED TO FORM CONTINUOUSLY VARIABLE POLAR PATTERNS MYOC, WNT3A, MEF2D ALDH1A1 3482/4885GSR 2610/4885
US-20260122416-A1 MICROPHONE ASSEMBLY AND SYSTEM ADAPTED TO FORM CONTINUOUSLY VARIABLE POLAR PATTERNS MYOC, MEF2D, GJB2 ALDH1A1 3991/4885GSR 1799/4885
US-20030069221-A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions CYP46A1, FABP2, SREBF1 ALDH1A1 1779/4885GSR 1970/4885
US-20260149923-A1 AUDIO SYSTEM FOR VEHICLE VRK1, GLI1, AVPR1A ALDH1A1 1073/4885GSR 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.